Intracranial and extracranial efficacy of lorlatinib in patients with ALK-Positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

21 Jul 2021

E Felip, A T Shaw, A Bearz, D R Camidge, B J Solomon, J R Bauman, T M Bauer, S Peters, F Toffalorio, A Abbattista, H Thurm, G Peltz, R Wiltshire, B Besse

Annals of Oncology, 2021 May

Link all’abstract

Forse può anche interessarti